MedTrace Logo

Pharmacodynamic and Pharmacokinetic Study of PL-ASA

NCT04811625 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-04-25

No results posted yet for this study

Summary

A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose

Conditions

  • Healthy Volunteers

Interventions

DRUG

PL-ASA

Pharmacologic profile of different aspirin formulations

Sponsors & Collaborators

  • PLx Pharma

    lead INDUSTRY

Principal Investigators

  • Francesco Franchi, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2021-09-15
Completion
2021-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811625 on ClinicalTrials.gov